Trial Recruitment Closes On Novo’s Next Big Semaglutide Bet: Alzheimer’s Disease

Twin EVOKE Studies Aim To Prove Neurological Benefits

Semaglutide has become a game-changer in type 2 diabetes and overweight patients, but Novo Nordisk is hoping to prove it can also slow cognitive decline in Alzheimer’s disease. It’s a long shot, but two large Phase III studies are now well underway to show just that.

Novo Nordisk’s GLP-1 mimetic semaglutide has achieved blockbuster success in treating type 2 diabetes and obesity, but the company is betting heavily that it may one day also be a game-changer in Alzheimer’s disease.

The company has just closed recruitment into two large-scale and long-term Phase III studies – called EVOKE and EVOKE Plus – aimed at finding out if a once-daily dose of oral semaglutide can

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

02 May 2025

• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

30 Apr 2025

• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

30 Apr 2025

• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

29 Apr 2025

• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.